Safety and Dosimetry of a Long-lasting Radiolabeled Somatostatin Analogue 177Lu-DOTA-EB-TATE in Patients With Advanced Metastatic Neuroendocrine Tumors
Latest Information Update: 27 May 2024
At a glance
- Drugs Lutetium-177-DOTA-EB-TATE (Primary)
- Indications Neuroendocrine tumours
- Focus First in man; Pharmacokinetics
Most Recent Events
- 21 May 2024 According to Molecular Targeting Technologies, Inc. (MTTI) media release, data from this study will be presented at at 2024 Society of Nuclear Medicine and Molecular Imaging Annual Meeting in Toronto June 8-11 .
- 22 Oct 2018 New trial record